On the stock market since 2014, it operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $4.8M a year. A small number, but proof the product has real buyers.
There is $65.1M in the vault; even if every debt were paid off, $54.9M would remain.
A loss of $18.2M against $4.8M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, VSAR sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: VSAR is a high-risk stock — not yet profitable, and its future rides on its product catching on.